A detailed history of Norwood Financial Corp transactions in Biogen Inc. stock. As of the latest transaction made, Norwood Financial Corp holds 355 shares of BIIB stock, worth $61,695. This represents 0.11% of its overall portfolio holdings.

Number of Shares
355
Previous 355 -0.0%
Holding current value
$61,695
Previous $91,000 16.48%
% of portfolio
0.11%
Previous 0.14%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 11, 2024

SELL
$222.59 - $267.94 $6,677 - $8,038
-30 Reduced 7.79%
355 $91,000
Q3 2023

Oct 16, 2023

BUY
$253.3 - $285.89 $2,533 - $2,858
10 Added 2.67%
385 $98,000
Q2 2023

Jul 27, 2023

SELL
$275.25 - $318.06 $8,257 - $9,541
-30 Reduced 7.41%
375 $106,000
Q4 2022

Jan 13, 2023

SELL
$252.44 - $306.72 $2,524 - $3,067
-10 Reduced 2.41%
405 $0
Q1 2022

Apr 25, 2022

BUY
$193.77 - $244.14 $4,844 - $6,103
25 Added 6.41%
415 $87,000
Q4 2021

Feb 08, 2022

BUY
$223.92 - $287.77 $87,328 - $112,230
390 New
390 $93,000

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $25B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Norwood Financial Corp Portfolio

Follow Norwood Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Norwood Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Norwood Financial Corp with notifications on news.